KOR
ENG
CA103
Oncolytic gene therapy via
AR & mTOR pathways
CA103
CA103 is a bi-specific shRNA targeting mTOR and AR (androgen receptor) genes – leading factors to the growth of urological tumors – packaged in oncolytic adenovirus*. CA103 is being developed for the treatment of prostate cancer and benign prostate hyperplasia.
본사서울시 성동구 뚝섬로 1길 31 서울숲M타워 707호 Office707, Seoul-sup M tower, Dduksumro 1 gil 31, Seongdong-gu, Seoul, KoreaTEL02.969.9055FAX02.969.9056E-mailcurigin@curigin.co.kr
Copyright © All Right Reserved.
